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Gepotidacin is a first-in-class triazaacenaphthylene novel bacterial topoisomerase inhibitor 
(NBTI). The compound has successfully completed phase II trials for the treatment of acute 
bacterial skin/skin structure infections and for the treatment of uncomplicated urogenital 
gonorrhea. It also displays robust in vitro activity against a range of wild-type and fluoroquinolone-
resistant bacteria. Due to the clinical promise of gepotidacin, a detailed understanding of its 
interactions with its antibacterial targets is essential. Thus, we characterized the mechanism of 
action of gepotidacin against Staphylococcus aureus gyrase. Gepotidacin was a potent inhibitor of 
gyrase-catalyzed DNA supercoiling (IC50 ≈ 0.047 µM) and relaxation of positively supercoiled 
substrates (IC50 ≈ 0.6 µM). Unlike fluoroquinolones, which induce primarily double-stranded 
DNA breaks, gepotidacin induced high levels of gyrase-mediated single-stranded breaks. No 
double-stranded breaks were observed even at high gepotidacin concentration, long cleavage 
times, or in the presence of ATP. Moreover, gepotidacin suppressed the formation of double-
stranded breaks. Gepotidacin formed gyrase-DNA cleavage complexes that were stable for >4 h. 
In vitro competition suggests that gyrase binding by gepotidacin and fluoroquinolones are 
mutually exclusive. Finally, we determined crystal structures of gepotidacin with the S. aureus 
gyrase core fusion truncate with nicked (2.31 Å resolution) or with intact (uncleaved) DNA (2.37 
Å resolution). In both cases, a single gepotidacin molecule was bound midway between the two 
scissile DNA bonds and in a pocket between the two GyrA subunits. A comparison of the two 
structures demonstrates conformational flexibility within the central linker of gepotidacin, which 
may contribute to the activity of the compound.  
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 There is an unmet medical need for new drugs to combat the rise in antimicrobial resistance. 
This is especially true for pathogens that are resistant to fluoroquinolones because of the broad use 
of these drugs. Fluoroquinolone resistance most often results from specific mutations in DNA 
gyrase or topoisomerase IV, which are the cellular targets for this drug class.1-7  
 Gyrase and topoisomerase IV are ubiquitous enzymes that play essential roles in a number of 
critical nucleic acid processes.2, 8-10 Gyrase works in conjunction with topoisomerase I to maintain 
the overall negative superhelical density of bacterial chromosomes.8-9, 11-16 The enzyme also is 
responsible for removing positive supercoils that accumulate ahead of replication forks and 
transcription complexes.8-9, 11-16 Although topoisomerase IV may also play a role in alleviating this 
torsional stress, its primary function is to remove DNA knots and decatenate tangles generated 
during recombination and replication, respectively.8, 17-20 21-22 Gyrase and topoisomerase IV both 
alter DNA topology by making a transient staggered four-base pair double-stranded break in the 
sugar-phosphate backbone of one DNA segment, opening a gate in the cleaved double helix, and 
passing a second segment of DNA through the break. In order to maintain genomic integrity during 
the DNA cleavage event, gyrase and topoisomerase IV form covalent bonds between active site 
tyrosine residues and the newly formed 5’-termini of the cleaved DNA.2, 4-5, 23-24 This covalent 
enzyme-cleaved DNA complex, which is a requisite intermediate in the catalytic cycle of these 
type II topoisomerases, is known as the “cleavage complex.”2, 4-5, 23-24  
 Clinically relevant fluoroquinolones form specific interactions with gyrase and topoisomerase 
IV through a divalent metal ion that is chelated by the C3/C4 keto acid group on the quinolone 
ring.25-31 The chelated metal ion is coordinated by four water molecules, two of which interact with 
a highly conserved serine and an acidic residue that is four amino acids upstream.25-31 Once gyrase 
or topoisomerase IV cut the DNA, fluoroquinolones intercalate between the bases at the cleaved 
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scissile bonds on both strands of the double helix,25, 30, 32-33 which stabilizes the enzyme-mediated 
double-stranded break. The stabilization of these cleavage complexes ultimately results in the 
generation of permanent double-stranded DNA breaks in the bacterial chromosome and induces 
the SOS response.2-3, 5-7, 34-35 It also robs the cell of the critical catalytic activities of these two 
enzymes, which impairs replication and transcription and can lead to catastrophic mitotic events.2-
3, 5-7 Both gyrase and topoisomerase IV contribute to cell death, however, the relative contributions 
of the two enzymes are both species and fluoroquinolone dependent.2-3, 5-7  
 Alterations in the conserved serine or acidic residue that anchor the “water-metal ion bridge” 
are the most common mutations associated with fluoroquinolone resistance.2-3, 5-7, 34-35 The 
overuse/misuse of this drug class, coupled with the fact that neither of these amino acid residues 
are essential for enzyme function, has led to a significant rise in fluoroquinolone resistance, which 
is threatening the clinical usefulness of these drugs.2-3, 5-7, 35 Because gyrase and topoisomerase IV 
are highly validated antimicrobial targets, this drug resistance has led to a search for novel 
compounds that are structurally distinct from the fluoroquinolones, but still display activity 
towards these two enzymes. This search resulted in the development of a new class of compounds 
known as “novel bacterial topoisomerase inhibitors,” or NBTIs (Figure 1).25 Although several 
NBTIs display potent antibacterial activity against a variety of strains, including those that are 
resistant to fluoroquinolones, relatively little has been published about their biochemical 
interactions with gyrase or topoisomerase IV.7, 25, 36-43 All reported NBTIs inhibit enzyme activity, 
whereas a few also enhance enzyme-mediated DNA cleavage.7, 25, 36-42 However, in contrast to 
fluoroquinolones, which induce primarily double-stranded DNA breaks, these NBTIs reportedly 
stabilize primarily enzyme-mediated single stranded breaks.25, 44 
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 The most clinically advanced NBTI is gepotidacin (Figure 1).45-47 This first-in-class 
triazaacenaphthylene-based compound is one of a very few antibacterials currently in active 
development that acts by a novel mechanism.48 Gepotidacin has successfully completed phase II 
trials for the treatment of acute bacterial skin/skin structure infections (including those caused by 
Staphylococcus aureus) and for the treatment of uncomplicated urogenital gonorrhea with no 
significant adverse events.45-47 It also displays robust in vitro activity against a range of bacterial 
species, including fluoroquinolone-resistant strains.43 
 Despite the clinical promise of gepotidacin, nothing has been reported for this compound 
regarding its interactions with any bacterial type II topoisomerase. Therefore, we characterized the 
actions of gepotidacin against S. aureus gyrase. The compound was a potent inhibitor of gyrase 
catalytic activity. Furthermore, it induced high levels of gyrase-mediated single-stranded DNA 
breaks; no double-stranded breaks were observed even at high gepotidacin concentrations, 
extended reaction times, or in the presence of ATP. Finally, to further characterize gepotidacin 
interactions, we determined two crystal structures of gepotidacin with a S. aureus gyrase core 
fusion truncate. One contained nicked duplex DNA (at 2.31Å resolution) and the other contained 
an intact (uncleaved) DNA substrate (2.37Å resolution). Each structure contained a single 
molecule of the compound. In both cases, the left-hand side (triazaacenaphthylene) of gepotidacin 
sat in a pocket on the twofold axis in the DNA midway between the two DNA cleavage sites, and 
the right-hand side (pyranopyridine) was situated in a pocket on the twofold axis between the two 
GyrA subunits. Our work provides important mechanistic insight into how gepotidacin acts against 
its bacterial target. 
MATERIALS AND METHODS 
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 Enzymes and Materials. Full-length wild-type S. aureus gyrase subunits (GyrA and GyrB, 
used for enzymological studies), as well as the wild-type gyrase core fusion truncate (GyrB27-
A56) and a fusion truncate containing a GyrAY123F mutation (used for structural studies) were 
expressed and purified as described previously.25 
Negatively supercoiled pBR322 DNA was prepared from Escherichia coli using a Plasmid 
Mega Kit (Qiagen) as described by the manufacturer. Positively supercoiled pBR322 DNA was 
prepared by treating negatively supercoiled molecules with recombinant Archaeoglobus fulgidus 
reverse gyrase.49-50 The number of positive supercoils induced by this process is comparable to the 
number of negative supercoils in the original pBR322 preparations.49 In the experiments that 
compared negatively and positively supercoiled DNA, the negatively supercoiled plasmid 
preparations were processed identically to the positively supercoiled molecules except that 
reaction mixtures did not contain reverse gyrase. Relaxed pBR322 plasmid DNA was generated 
by treating negatively supercoiled pBR322 with calf thymus topoisomerase I (Invitrogen) and 
purified as described previously.27 
Gepotidacin was provided by GlaxoSmithKline. Moxifloxacin was obtained from LKT 
Laboratories. Gepotidacin and moxifloxacin were stored at 4 ºC as 20 mM stock solutions in 100% 
dimethyl sulfoxide.  
 DNA Supercoiling and Relaxation. DNA supercoiling/relaxation assays were based on 
previously published protocols by Aldred et al.26, 51 Assays contained 20 nM gyrase, 5 nM relaxed 
or positively supercoiled pBR322, 1.5 mM ATP, 1 mM dithiothreitol in 20 μL of 50 mM Tris-HCl 
(pH 7.7), 20 mM KCl, 300 mM KGlu, 5 mM MgCl2, and 0.05 mg/mL bovine serum albumin. 
Reactions were incubated at 37 C for 25 min (DNA supercoiling assays) or 0.5 min (DNA 
relaxation assays), unless stated otherwise. The chosen assay lengths represent the minimum time 
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required to completely negatively supercoil relaxed DNA or to relax positively supercoiled DNA 
in the absence of drug. Reaction mixtures were stopped by the addition of 3 µL of a mixture of 
0.77% SDS and 77.5 mM EDTA. Samples were mixed with 2 µL of loading buffer [60% sucrose, 
10 mM Tris-HCl (pH 7.9), 0.5% bromophenol blue, and 0.5% xylene cyanol FF] and were 
incubated at 45 ºC for 2 min before being subjected to electrophoresis on 1% agarose gels in 100 
mM Tris-borate (pH 8.3) and 2 mM EDTA. Gels were stained with 1 µg/mL ethidium bromide for 
30 min and DNA bands were visualized with medium-range ultraviolet light and quantified using 
an Alpha Innotech digital imaging system. IC50 values were calculated using nonlinear regression, 
three parameter curve fit using GraphPad Prism software.  
DNA Cleavage. DNA cleavage reactions were based on the procedure of Aldred et al.26 
Reactions were carried out in the presence or absence of gepotidacin or moxifloxacin and 
contained 75 nM S. aureus gyrase (A2B2) and 10 nM positively or negatively supercoiled pBR322 
in 20 µL of cleavage buffer [50 mM Tris-HCl (pH 7.5), 100 mM KGlu, 5 mM MgCl2, 1 mM 
dithiothreitol, and 50 µg/mL bovine serum albumin]. In some cases, 1.5 mM ATP was included in 
reaction mixtures or the MgCl2 in the cleavage buffer was replaced with 5 mM CaCl2. Unless 
stated otherwise, reactions were incubated at 37 ºC for 30 min. Enzyme-DNA cleavage complexes 
were trapped by adding 2 µL of 5% SDS followed by 2 μL of 250 mM EDTA and 2 µL of 0.8 
mg/mL Proteinase K (Sigma Aldrich). Reaction mixtures were incubated at 45 ºC for 30 min to 
digest gyrase. Samples were mixed with 2 µL of loading buffer and were incubated at 45 ºC for 2 
min before loading onto 1% agarose gels. Reaction products were subjected to electrophoresis in 
a buffer of 40 mM Tris-acetate (pH 8.3) and 2 mM EDTA that contained 0.5 µg/mL ethidium 
bromide. DNA bands were visualized and quantified as described above. DNA single- or double-
stranded cleavage was monitored by the conversion of supercoiled plasmid to nicked or linear 
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molecules, respectively, and quantified in comparison to a control reaction in which an equal 
amount of DNA was digested by EcoRI (New England BioLabs). EC50 values were calculated 
using nonlinear regression, three parameter curve fit using GraphPad Prism software. 
 Stability of Gyrase-DNA Cleavage Complexes. The persistence of gyrase-DNA cleavage 
complexes in the absence or presence of gepotidacin or moxifloxacin was determined using the 
procedure of Aldred et al.26 Initial reaction mixtures contained 375 nM gyrase, 50 nM negatively 
supercoiled pBR322, and 5 µM gepotidacin or 25 µM moxifloxacin in 20 µL of cleavage buffer. 
In experiments carried out in the absence of drug, the MgCl2 in the cleavage buffer was replaced 
with 5 mM CaCl2 to increase baseline levels of DNA cleavage.
51-52 Reaction mixtures were 
incubated at 37 ºC for 30 min to allow cleavage complexes to form, and were then diluted 20–fold 
with 37 ºC cleavage buffer that lacked divalent metal ion. Samples (20 µL) were removed at times 
ranging from 0–240 min. DNA cleavage was stopped and samples were processed, visualized, and 
quantified as described above. Levels of gepotidacin-induced single-stranded or moxifloxacin-
induced double-stranded DNA cleavage were set to 100% at time zero, as was enzyme-mediated 
DNA cleavage in the absence of drug. The persistence (stability) of cleavage complexes was 
determined by the loss of single- or double-stranded DNA cleavage, respectively, over time. 
Crystallization of Gepotidacin in Complexes with S. aureus Gyrase. Crystals of 
gepotidacin with the S. aureus gyrase core fusion truncate (GyrB27-A56) that contained a 
GyrAY123F mutation and 20-12p-8 duplex DNA were grown by microbatch under oil and frozen as 
described previously (Table S1).25, 53 The position of the nicks were at the scissile bonds. A 
schematic of the gyrase truncate is shown in Figure S1. The 20-12p-8 is a 20mer DNA duplex 
made by annealing complementary 8mers and 12mers such that the four base-pair overhang from 
the 12mers is complementary (Table S2; Watson strand: 5’-AGCCGTAG-3’ + 5’-
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GTACCTACGGCT-3’; Crick strand: 5’-AGCCGTAG-3’ + 5’-GTACCTACGGCT-3’).25 The 
12mer contains a 5’ phosphate moiety, equivalent to the scissile phosphate, but not covalently 
linked to the 3’ OH of the preceding nucleotide or Tyr123 of GyrA. The symmetric doubly nicked 
DNA was used because it has been optimized to provide diffractable crystals with NBTIs.25, 53 
Gepotidacin also was crystallized with the wild-type S. aureus gyrase core fusion truncate and an 
intact (uncleaved) symmetric homoduplex DNA (Table S2; 20-444T). Note that in crystal 
structures of NBTIs formed with asymmetric DNA substrates (Table S2), the DNA has static 
disorder around the same axis of the complex.53-55  
Data to 2.31Å were collected on a single frozen crystal of gepotidacin with the S. aureus 
gyrase core fusion truncate containing a GyrAY123F mutation and the symmetrically nicked 20-
12p-8 duplex DNA on beamline ID23-2 at the ESRF on a Mar 225 CCD.25 Data were processed 
and merged with HKL and SCALEPACK56, the structure was solved by rigid body refinement 
from other structures in the same cell (PDB codes: 2xcs, 5iwi),25 and refined with refmac57 and 
phenix.refine.58 The restraint dictionary for gepotidacin was made with Acedrg.59 The 2.37Å 
gepotidacin crystal with the gyrase core fusion truncate and the intact 20-444T DNA was in a 
different cell from previously reported NBTI crystal structures. This 2.37Å structure was solved 
by molecular replacement using the domain from 2xcs and refined with refmac.59 The 
crystallographic details for both structures are given in Table S1.  
The deposited crystallographic coordinates, each of which represents the millions of 
complexes in the crystal, contain two ‘equivalent’ orientations of the compound, related by C2 
symmetry. In any one complex there will only be one compound bound, and single biological 
complexes with one compound can be readily derived from the crystal structures. Biologically 
relevant complexes with NBTIs are now available at 
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https://www.cardiff.ac.uk/people/view/1141625-bax-benjamin (Click on Research tab). Note that 
NBTIs bind in two pockets on the twofold axis of the complex, which are named 2D (pocket 
in DNA), and pocket 2A (pocket between the two GyrA subunits). NBTI complexes use a 
nomenclature which is non-conventional by PDB standards, because the structures are of a fusion 
protein in which residues from the C-terminal region of S. aureus GyrB (409-644) have been fused 
to amino-acids from the N-terminus of GyrA (2-491). In our standard ‘BA-x’ nomenlature the 
residues in the first GyrBA fusion have CHAINID B if they are from GyrB and CHAINID A, if 
they are from GyrA. This nomenclature is extended to inhibitors which are given CHAINID I – 
for inhibitor. NBTIs are given the residue number 2 (i.e., I2), for the ‘second’ inhibitor site on the 
twofold axis (the first site which stabilizes cleavage complexes is the cleavage site, occupied by 
inhibitors such as fluoroquinolones).  
In structural figures that were created using Pymol60, carbon atoms in the DNA are green, 
those in the first GyrBA core fusion truncate subunit are cyan/blue in GyrA and magenta in GyrB, 
and those in the second subunit are grey or black. Carbon atoms in NBTIs are yellow or orange, 
and oxygen, nitrogen, and sulfur atoms are red, blue, and yellow, respectively. Water molecules 
are shown as small red spheres.  
RESULTS AND DISCUSSION 
  Inhibition of Gyrase Catalytic Activity by Gepotidacin. Gyrase has two primary functions 
in the bacterial cell. First, it generates negative supercoils in DNA and works in conjunction with 
topoisomerase I to establish and maintain the superhelical density of the bacterial chromosome. 
Second, it is responsible for removing the positive supercoils that accumulate ahead of replication 
forks and transcription complexes.8-9, 11-14, 16 NBTIs were first reported by Coates et al. as a novel 
class of antibacterials61 and subsequently were described as a class of compounds that inhibited 
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the DNA supercoiling reaction of gyrase.7, 25, 36-38, 62 Therefore, because of the two critical activities 
of gyrase in the bacterial cell, the effects of gepotidacin on enzyme-catalyzed DNA supercoiling 
and relaxation of positively supercoiled DNA were investigated.  
 As a prelude to the inhibition experiments, S. aureus gyrase activity was assessed in the 
absence of gepotidacin. Starting with positively supercoiled DNA, we followed the time course 
for the enzyme to remove the positive supercoils and then convert the relaxed DNA to a negatively 
supercoiled plasmid. As reported previously for gyrase from Bacillus anthracis, Escherichia coli, 
and Mycobacterium tuberculosis,63-64 the S. aureus enzyme removed positive supercoils more 
rapidly than it introduced negative supercoils into relaxed DNA (Figure 2). Whereas all of the 
positive supercoils were gone within 60 s, it took ~20 min to convert the plasmid into fully 
negatively supercoiled DNA. This ~20-fold time difference between the two reactions likely 
reflects the acute temporal requirement to rapidly remove positive supercoils that accumulate in 
front of the replication fork as compared to the maintenance of steady state levels of negative DNA 
supercoiling.63-64  
 As seen in Figure 3, gepotidacin was a potent inhibitor of gyrase activity. The IC50 for 
inhibition of DNA supercoiling (top left panel) was ~0.047 µM and that for the relaxation of 
positive DNA supercoils (top right panel) was ~0.6 µM. In contrast, the IC50 values for the 
inhibition of supercoiling and relaxation by moxifloxacin, a clinically relevant fluoroquinolone 
were ~11.5 µM (bottom left panel) and ~73 µM (bottom right panel), respectively. Thus, 
gepotidacin is considerably more potent (~240- and 120-fold, respectively) than moxifloxacin in 
its ability to inhibit the two critical catalytic functions of S. aureus gyrase.  
 Enhancement of Gyrase-mediated DNA Cleavage by Gepotidacin. Because some NBTIs 
induce DNA scission by bacterial type II topoisomerases,7-8, 24-25, 38, 44 we examined the effects of 
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gepotidacin on the ability of S. aureus gyrase to cleave DNA (Figure 4). In contrast to 
fluoroquinolones, which generate primarily double-stranded DNA breaks, all of the breaks created 
in the presence of gepotidacin were single-stranded. Furthermore, when gyrase was left out of 
reaction mixtures, no DNA cleavage was observed even at 200 µM gepotidacin and incubation 
times (3 h) that were 6 times longer than normally used. 
 Initial experiments to further characterize the induction of gyrase-mediated DNA cleavage by 
gepotidacin utilized negatively supercoiled plasmid (Figure 5, left panel, blue). Gepotidacin 
strongly enhanced gyrase-mediated DNA cleavage in the nanomolar range [EC50 (concentration 
required to induce 50% maximal DNA cleavage) ≈ 0.13 µM] and generated single-stranded DNA 
breaks in more than 30% of the initial substrate at low micromolar concentrations. Moreover, 
gepotidacin was considerably more potent than moxifloxacin, which required micromolar levels 
to induce substantial levels of double-stranded DNA cleavage (EC50 ≈ 2 µM) (Figure 5, right panel, 
black).  
 Because drug-stabilized cleavage complexes formed on positively supercoiled DNA ahead of 
replication forks and transcription complexes are most likely to be converted into permanent strand 
breaks,7-8, 24 we also examined the effects of gepotidacin on gyrase-mediated cleavage of positively 
supercoiled DNA (Figure 5, left panel, red). As reported for other species of gyrase with 
fluoroquinolones and NBTI-like compounds,31, 44, 63-64 gepotidacin induced ~2–fold lower levels 
of single-stranded breaks in the presence of the S. aureus enzyme and positively supercoiled as 
compared to negatively supercoiled plasmid. In addition, the potency of gepotidacin with 
positively supercoiled DNA was slightly higher than that seen with negatively supercoiled 
substrate (EC50 ≈ 0.18 µM). As with negatively supercoiled plasmid, no double-stranded breaks 
were observed.  
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 In contrast to the results with the NBTI, the efficacy of moxifloxacin-induced double-stranded 
breaks in positively supercoiled plasmid (Figure 5, right panel, green) was similar to that seen with 
negatively supercoiled DNA. However, the potency of the drug fell ~8–fold with positively 
supercoiled substrates (EC50 ≈ 17 or 2 µM with positively or negatively supercoiled DNA, 
respectively). As above, gepotidacin was considerably (~10– to 100–fold) more potent against S. 
aureus gyrase than moxifloxacin.  
 Some topoisomerase II-targeted drugs, such as the anticancer drug etoposide, induce 
predominantly single-stranded breaks at low concentrations with either eukaryotic or prokaryotic 
type II topoisomerases; however, double-stranded breaks become more prevalent at increasing 
drug concentrations.65-67 It is assumed that this change from single- to double-stranded DNA 
cleavage reflects a decreased affinity for the binding of the second drug molecule. Thus, to 
determine whether gepotidacin displays a similar ability to induce gyrase-mediated double-
stranded breaks at high concentrations, DNA cleavage assays were carried out in the presence of 
200 µM compound, which is ~40 times the concentration needed to induce maximal levels of 
single-stranded DNA breaks (Figure 6). The DNA cleavage profile for 200 µM gepotidacin was 
identical to that observed for 5 µM compound, even over a time course that was 6 times longer 
than used under standard conditions (Figure 6). As seen at lower drug concentrations, only single-
stranded breaks were observed.  
 Although gyrase does not require ATP in order to cleave DNA, the high energy cofactor is 
necessary for DNA strand passage and enzyme turnover.2, 5 The DNA cleavage assays shown in 
earlier figures did not include ATP in reaction mixtures. Therefore, the effects of gepotidacin on 
gyrase-mediated DNA cleavage were carried out in the presence of 1.5 mM ATP to determine 
whether the high-energy cofactor affects the ability of the compound to generate single- vs. double-
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stranded DNA breaks (Figure 7). Whereas the compound is more potent in the presence of ATP 
(EC50 ≈ 0.04 µM as compared to EC50 ≈ 0.13 µM in the absence of ATP), no double-stranded 
DNA cleavage was observed.  
 Taken together the above data lead to the conclusion that gepotidacin induces only single-
stranded DNA breaks mediated by S. aureus gyrase.  
 Gepotidacin Induces Stable Gyrase-DNA Cleavage Complexes. In general, the ability of 
topoisomerase-targeted drugs to kill cells correlates with the stability of cleavage complexes 
formed in their presence.68 Therefore, we examined the stability of S. aureus gyrase-DNA cleavage 
complexes that were generated in gepotidacin-containing reactions. This was accomplished by 
monitoring the decay in DNA scission following a 20-fold dilution of reaction mixtures into a 
buffer that lacked the divalent metal ion required for cleavage. This assay is believed to reflect the 
rate at which the ternary gyrase-DNA-drug complex dissociates, given that these complexes are 
unlikely to re-form in a diluted reaction mixture that lacks substantial levels of divalent metal ion. 
As seen in Figure 8, gyrase-DNA cleavage complexes formed in the presence of gepotidacin were 
highly stable and displayed little dissociation even 4 h after dilution. The stability of these single-
stranded DNA cleavage complexes appeared to be similar to or marginally greater than that of the 
doubly cleaved counterparts generated in the presence of moxifloxacin. In contrast, in the absence 
of the NBTI or fluoroquinolone the lifetime of single- or double- stranded DNA cleavage 
complexes formed by S. aureus gyrase following dilution was <10 s.  
 Gepotidacin Suppresses Gyrase-Mediated Double-Stranded DNA Cleavage. Cleavage of 
the two strands of the double helix by type II topoisomerases are coordinated but individual events 
(i.e., cleavage at one scissile bond does not necessarily affect cleavage at the other).65 Thus, the 
single-stranded DNA cleavage that occurs in the presence of gepotidacin can reflect two possible 
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mechanisms. Either the compound induces cleavage at only one of the two scissile bonds in any 
cleavage complex or the cleavage of one scissile bond in the presence of gepotidacin alters the 
enzyme-DNA complex such that the second DNA strand cannot be cut. This latter mechanism is 
supported by a structural model that suggests that the second strand is only cleaved when S. aureus 
gyrase adopts an asymmetric conformation after the first strand has been cleaved.65-67 NBTIs are 
believed to block the transformation to the asymmetric conformation, thus preventing cleavage of 
the second strand.65-67 This mechanism is consistent with the single-stranded DNA cleavage 
induced by Mycobacterium tuberculosis gyrase inhibitors (MGIs), which constitute a subclass of 
NBTIs optimized for activity against M. tuberculosis gyrase.44 
 Unfortunately, the low baseline level of double-stranded DNA cleavage mediated by S. 
aureus gyrase makes it difficult to distinguish between these two possibilities. To overcome this 
difficulty, we substituted the MgCl2 in DNA cleavage assays with CaCl2 (Figure 9). Although the 
fundamental properties of DNA cleavage and ligation are not altered by this substitution,51-52 
baseline levels of enzyme-mediated double-stranded DNA cleavage in the presence of Ca2+ 
(~15%) are substantially higher as compared to those observed in Mg2+-containing reactions 
(<1%). As seen in Figure 9, the rise in single-stranded DNA cleavage induced by increasing 
concentrations of gepotidacin was accompanied by a coordinate decrease in levels of double-
stranded DNA cleavage. This result provides strong evidence that cleavage of one scissile bond in 
the presence of gepotidacin suppresses the ability of S. aureus gyrase to cleave the scissile bond 
on the opposite strand.  
 Gepotidacin Can Displace Moxifloxacin from the Active Site of S. aureus Gyrase. 
Previous structural studies with NBTIs indicate that they bind to bacterial type II topoisomerases 
at the DNA cleavage active site and interact with the DNA between the two scissile bonds.25, 54-55 
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Although their site of interaction within the enzyme-DNA complex is not identical to those of 
fluoroquinolones (which interact at the two cleaved scissile bonds), a modeling study suggested 
that moxifloxacin and the MGI GSK000 and moxifloxacin could not coexist in a cleavage complex 
formed by M. tuberculosis gyrase.44 Therefore, a cleavage competition assay was carried out to 
determine whether gepotidacin and moxifloxacin could occupy the same cleavage complex 
established with S. aureus gyrase. In this assay, cleavage complexes were formed in the presence 
of a mixture of 25 µM moxifloxacin and increasing concentrations of gepotidacin (0-100 µM). 
Competition was monitored by the loss of double-stranded DNA breaks, which could have been 
induced only by moxifloxacin. As seen in Figure 10, levels of double-stranded breaks dropped 
~95% in the presence of 100 µM gepotidacin, which indicates that the binding of the NBTI and 
moxifloxacin in the active site of the S. aureus gyrase-DNA cleavage complex are mutually 
exclusive.  
 Structure of the S. aureus gyrase-DNA-Gepotidacin Ternary Complex. Given the results 
of the competition studies and the fact that previous NBTIs have been localized to the DNA 
cleavage active site of bacterial type II topoisomerases, we further examined gepotidacin 
interactions within the enzyme-DNA complex. To this end, two crystal structures of gepotidacin 
with the S. aureus core fusion truncate were determined (Tables S1, S2). A schematic of the 
truncate is shown in Figure S1. The first structure (2.31Å resolution) included a truncate that 
contained a GyrAY123F mutation and a doubly nicked 20 base pair DNA duplex (Figure 11 and 
Figure S2, which contains an animation). Because the binding pocket for gepotidacin is on the 
twofold axis of the complex, the electron density observed is an average of two equivalent binding 
modes for the compound related by the C2 axis of the complex. The second structure (2.37Å 
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resolution) included a wild-type gyrase truncate and an intact (uncleaved) 20 base pair DNA 
substrate (Figure 12).  
 The binding mode we observed for gepotidacin is similar to that reported previously for other 
NBTIs, including GSK945237 (Figure S3).25, 54-55 In contrast to fluoroquinolones, which bind in 
the DNA at the two four base-pair separated cleavage sites,25, 30, 32-33 only a single molecule of 
gepotidacin binds in the S. aureus gyrase-DNA complex.  
 The left-hand side (triazaacenaphthylene) of gepotidacin sits in a pocket in the DNA on the 
twofold axis of the complex (pocket 2D), midway between the two DNA cleavage sites, and the 
right-hand side (pyranopyridine) sits in a pocket on the twofold axis between the two GyrA 
subunits (pocket 2A; Figures 11 and 12). Pocket 2A does not exist in the apo structure25 or in a 
binary complex of uncleaved DNA with S. aureus DNA gyrase.69 It is notable that there is a 
relative movement of the two GyrA subunits of about 1.2Å in the two gepotidacin crystal 
structures. As a result, when the two structures are aligned on the basis of the GyrA subunits, the 
right-hand side and left-hand side of gepotidacin are not in identical positions (Figure 12). This 
finding strongly suggests that there is flexibility about the central linker of gepotidacin. The 
flexibility may allow the compound to remain stably bound to multiple different enzyme-DNA 
complexes, including those that contain intact or nicked DNA substrates. This attribute may 
explain how some NBTIs inhibit gyrase activity without enhancing cleavage, while others are able 
to do both.7, 25, 36-42  
CONCLUSIONS  
 Due to the rise in antibacterial drug resistance, there is a critical need for the development of 
new agents that retain activity against resistant infections. One approach, which led to the 
development of the NBTIs, is to identify compounds that work against validated clinical targets, 
 18 
such as the bacterial type II topoisomerases, gyrase and topoisomerase IV, and retain activity 
against fluoroquinolone-resistant enzymes. Although gepotidacin and other NBTIs bind in the 
same DNA cleavage active site of gyrase as fluoroquinolones, they display distinct interactions. 
Whereas, fluoroquinolones interact with S. aureus gyrase through water-mediated contacts with 
Ser84 and Glu88 in the GyrA subunit, the basic nitrogen of gepotidacin interacts directly with 
GyrA Asp83 from one subunit, and indirectly via a water molecule with Asp83 from the second 
GyrA subunit.25-31 Hence, NBTIs and related compounds are able to retain activity against the most 
common gyrase mutations that are resistant to clinically relevant fluoroquinolones.  
 Gepotidacin is a first-in-class triazaacenaphthylene NBTI. Despite its success in clinical trials 
against skin/skin structure infections (such as those caused by S. aureus) and uncomplicated 
urogenital gonorrhea,45-47 nothing had been reported about its interactions with its bacterial type II 
topoisomerase targets. Therefore, the current work characterized the activity of the compound 
against S. aureus gyrase. Gepotidacin was a potent inhibitor of gyrase activity and enhanced 
enzyme-mediated DNA cleavage. In contrast to fluoroquinolones, the compound enhanced only 
single-stranded DNA breaks. Further studies will be required to determine whether our proposed 
model for how gepotidacin blocks gyrase-mediated cleavage of the second strand is correct. 
However, as discussed above, we propose that the compound prevents the enzyme from attaining 
the asymmetric conformation that is necessary to promote cleavage at the second strand. Finally, 
it will be interesting to determine how the stimulation of enzyme-mediated DNA cleavage and the 
inhibition of type II topoisomerases ultimately contribute to bacterial cell death following 
treatment with gepotidacin.  
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Figure Legends 
Figure 1: Structure of the novel bacterial topoisomerase inhibitor (NBTI) gepotidacin 
(GSK2140944). Gepotidacin is composed of a triazaacenaphthylene on the left-hand side (LHS), 
a central linker region, a basic nitrogen, and a pyranopyridine on the right-hand side (RHS).  
Figure 2: S. aureus gyrase removes positive supercoils more rapidly than it introduces negative 
supercoils into relaxed DNA. Time courses are shown for the relaxation of positively supercoiled 
plasmid followed by the introduction of negative supercoils (top) and the negative supercoiling of 
relaxed plasmid (bottom). The positions of positively supercoiled [(+)SC], relaxed, and negatively 
supercoiled [(−)SC] DNA are indicated on the gels. The gel images are representative of at least 
three independent experiments. 
Figure 3: Gepotidacin and moxifloxacin inhibit DNA supercoiling and relaxation reactions 
catalyzed by S. aureus gyrase. The effects of gepotidacin (blue, top panels) and moxifloxacin (red, 
bottom panels) on the supercoiling of relaxed DNA (left panels) and the relaxation of positively 
supercoiled DNA (right panels) are shown. Error bars represent the standard deviation (SD) of at 
least three independent experiments. 
Figure 4: Gepotidacin induces single-stranded DNA breaks in the presence of gyrase. The gel 
shows DNA products following cleavage reactions containing 5 or 200 µM gepotidacin or 
moxifloxacin in the absence or presence of S. aureus gyrase. The positions of negatively 
supercoiled [(−)SC], nicked (Nick), and linear (Lin) DNA are indicated on the gels. The generation 
of single- and double-stranded DNA breaks were monitored by the conversion of negatively 
supercoiled substrates to nicked and linear DNA products, respectively. The gel images are 
representative of at least three independent experiments. 
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Figure 5: Gepotidacin is a potent enhancer of gyrase-mediated single-stranded DNA cleavage. 
The left panel shows the effects of gepotidacin on S. aureus gyrase-mediated single- (SS, closed 
circles) and double-stranded (DS, open circles) DNA cleavage of negatively (blue) and positively 
(red) supercoiled DNA. The right panel shows the effects of moxifloxacin on gyrase-mediated 
single- and double-stranded DNA cleavage of negatively (black) and positively (green) 
supercoiled DNA. Error bars represent the SD of at least three independent experiments. The gels 
shown at the top are representative cleavage assays with negatively supercoiled DNA. The 
mobilities of negatively supercoiled DNA [(−)SC], nicked circular DNA (Nick), and linear DNA 
(Lin) are indicated on the gels.  
Figure 6: Gepotidacin stabilizes only single-stranded DNA breaks mediated by S. aureus gyrase. 
The enhancement of single-stranded (SS, closed circles) and double-stranded (DS, open circles) 
DNA cleavage over time in the presence of 5 µM (blue) and 200 µM (red) gepotidacin are shown. 
Error bars represent the SD of at least three independent experiments.  
Figure 7: Gepotidacin enhances only single-stranded DNA breaks mediated by S. aureus gyrase 
in the presence of ATP. The enhancement of gyrase-mediated single-stranded (SS, closed circles) 
or double-stranded (DS, open circles) DNA breaks generated by gyrase in the presence of 1.5 mM 
ATP is shown. Error bars represent the SD of at least three independent experiments. 
Figure 8: Gepotidacin induces stable DNA cleavage complexes formed by S. aureus gyrase. The 
persistence of ternary gyrase–DNA–drug cleavage complexes was monitored by the loss of single-
stranded DNA breaks in the presence of 5 µM gepotidacin (blue) or double-stranded DNA 
cleavage in the presence of 25 µM moxifloxacin (red), or the loss of single- (open circle, white) or 
double-stranded DNA cleavage in the absence of drug (closed circle, black). Levels of DNA 
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cleavage were set to 100% at time zero to allow for direct comparisons. Error bars represent the 
SD of at least three independent experiments.  
Figure 9: Gepotidacin suppresses double-stranded DNA breaks generated by S. aureus gyrase. 
The effects of gepotidacin on S. aureus gyrase-mediated single-stranded (SS, closed circles) and 
double-stranded (DS, open circles) DNA cleavage are shown. Reactions were carried out in the 
presence of Ca2+ rather than Mg2+ to increase levels of baseline DNA cleavage. Error bars represent 
the SD of at least three independent experiments. The gel shown at the top is representative of at 
least three independent experiments. The mobilities of negatively supercoiled DNA [SC], nicked 
DNA (Nick), and linear DNA (Lin) are indicated on the gels.  
Figure 10: The actions of gepotidacin and moxifloxacin on S. aureus gyrase-mediated DNA 
cleavage are mutually exclusive. A DNA cleavage/ligation equilibrium was formed in the presence 
of a saturating concentration of moxifloxacin (25 µM) plus 0-100 µM gepotidacin. Competition 
was monitored by the loss of moxifloxacin-induced double-stranded DNA breaks. Error bars 
represent the SD of at least 3 independent experiments.  
Figure 11: Views of a gepotidacin complex formed with S. aureus gyrase and doubly nicked DNA 
at a resolution of 2.31Å. The top left panel shows gepotidacin binding on the twofold axis of the 
complex midway between the two DNA cleavage sites; the top right panel is an approximately 
orthogonal (90º) view of the same structure. The bottom left and right panels show the same views 
as the corresponding top panels, but zoomed out to show the subunits of gyrase. In these panels, 
gepotidacin is shown as spheres, DNA with semi-transparent surface, and proteins as ribbons. In 
all panels, carbon atoms in the DNA are green, those in the first GyrBA core fusion truncate subunit 
are cyan/blue in GyrA and magenta in GyrB, and those in the second subunit are grey or black. 
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Carbon atoms in gepotidacin are yellow, and oxygen, nitrogen, and sulfur atoms are red, blue, and 
yellow, respectively. Water molecules are shown as small red spheres. 
Figure 12: Comparison of two gepotidacin crystal structures with S. aureus DNA gyrase and 
DNA. (top panel) A 2.31Å crystal structure of gepotidacin with doubly nicked DNA (atoms not 
bonded are arrowed). (middle panel) A 2.37Å crystal structure of gepotidacin with intact 
(uncleaved) DNA. (bottom panel) Structures from top and middle are superimposed based on 
GyrA subunits shown with grey/black carbons. Note the ~1.2Å shift of atoms in the GyrA subunit 
with cyan/blue carbons and the similar shift in the right-hand side of gepotidacin. Colors are as 
shown in Figure 11, except that the carbon atoms in gepotidacin in the complex with intact DNA 
(middle and bottom panels) are shown in orange.  
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